Patients with arterial hypertension and obesity: targeting biomarkers as a personalised therapeutic approach

This literature review focuses on the treatment of patients with arterial hypertension (AH) and obesity, from the point of view of personalised medicine (PM). One of the PM approaches is the use of biochemical markers which reflect normal and pathologic processes in the human body, as well as the presence of a disease or the response to a treatment. In patients with AH and obesity, antihypertensive medications should also affect the levels of biomarkers. This requirement is met by perindopril, an angiotensin-converting enzyme (ACE) inhibitor with high tissue specificity. Pathogenetic therapy with perindopril provides an opportunity to target the biomarkers of adipokine activity, endothelial dysfunction, inflammation, and other processes.

1. Markers as a tool for personalized medicine / edited by Academician RAMN Kukes V. G. – Moscow: publishing house ANO The International Association of clinical pharmacologists and pharmacists, 2013. Russian. (Маркеры как инструмент персонализированной медицины. Под редакцией академика РАМН Кукеса В. Г. М.: Издательство АНО

2. Международная ассоциация клинических фармакологов и фармацевтов, 2013).

3.

4. Targonski P. V., Bonetti P. O., Pumper G. M. et al. Coronary endothelial dysfunction is associated with an increased risk of cerebrovascular events. Сirсulation. 2003; 107:2805–9.

5. Merisco C., Condorelli G., Orzi F. et al. Insulin-stimulated cardiac glucose uptake is impaired in spontaneously hypertensive rats role of early steps of insulin signaling. J. Hypertens. 2000; 18: 463–73.

6. Nissen S. E., Tuzcu E. M., Libby P. et al. Effects of antihypertensive agents on cardiovascular events in patients with coronary with coronary disease and normal blood pressure: The CAMELOT Study: a Randomized Controlled Trial. JAMA 2004; 292:2217–25.

7. Su T. C., Chien K. L., Jeng J. S. et al. Pulse pressure, aortic regurgitation and carotid atherosclerosis: a comparison between hypertensives and normotensives. Int. J. Clin. Pract. 2006; 60:134–40.

8. L. I. Yuan, WANG Xiao-ming et al. Effects of perindopril on sICAM-1 and Fas/Apo-1 in peripheral blood of elderly patients with congestive heart failure. Chinese J. Geriatric Cardiovascular and Cerebrovascular Disease 2004; 02:112–6.

9. Nedogoda S. V. et al. Obesity and hypertension. Part II: Features of antihypertensive therapy for obesity. Cardiovascular Therapy and Prevention. 2009; 1: 88–98. Russian. (Недогода С. В. и соавт. Ожирение и артериальная гипертензия. Часть II: особенности антигипертензивной терапии при ожирении. Кардиоваскулярная терапия и профилактика. 2009; 1:88–98).

10. Trayhurn P., Wood I. S. Signalling role of adipose tissue: adipokines and inflam-mation in obesity. Biochemical Society Transactions 2005; 33: 1078–81.

11.

12.

13.

14. Horm Metab Res 2002; 34:703–8.

15.

16.

17. Jandrain B. et al. Long-term acceptability of perindoprol in type II diabetic patients with hypertension. Am J Med 1992; 92:91–4.

18.

19.

20.

21.

22.

23.

24.

25.

26. дроме: влияние на адипокины, маркеры эндотелиальной дисфункции и системного воспаления. Лечащий врач 2011; 2:11–5).

27. Diet F., Pratt R. E., Berry G. J. et al. Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease. Circulation. 1996; 94:2756–67.

28.

29.

30.

31. риска). Исследование Премьера. Кардиология 2005; 46:21–2718).

32.

33.

34.

35.

36.

37. в широкой клинической практике. Consilium Medicum. 2002; 4 (3):125–9).

38.

39.